Fig. 5.

Trial counts and fractions of biological and mAbs trials for the 20 most common cancers. (A) Most biological cancer intervention trials are registered for leukaemias and non-Hodgkin lymphoma. Lung cancer, the cancer with the highest mortality, ranks only sixth in this statistic. (B) Biological interventions are registered for 6% of non-cancer trials. This fraction is higher for all of the 20 most common cancers and more than twice as high for 18 out of those 20. The fraction is more than 3 times as high for 10 cancer conditions still. (C) Non-Hodgkin lymphoma and leukaemias also have the highest count of mAb trials among the 20 most common cancers. (D) As for biological interventions, in general mAbs play a more important role in all 20 cancer conditions compared with non-cancer conditions. Table III lists a comprehensive set of data relating to the subgroup counts for the 20 cancers analysed in Figs 4 and 5.